Pandite Arundathy N.
Known title: Chief Medical OfficerCIK: 0001827232
Associated companies
Transaction History
| STTK | ▼ Sell | Open Market | 30,000 | $210K | 6/30/2026 | View on chart |
| STTK | ▼ Sell | Open Market | 30,000 | $198K | 5/12/2026 | View on chart |
| STTK | ▼ Sell | Tax Withholding | 3,195 | $13K | 1/25/2026 | View on chart |
| STTK | ▼ Sell | Tax Withholding | 6,851 | $33K | 1/10/2026 | View on chart |
| STTK | ▼ Sell | Tax Withholding | 3,211 | $4K | 1/25/2025 | View on chart |
| STTK | ▼ Sell | Tax Withholding | 6,884 | $8K | 1/10/2025 | View on chart |
| STTK | ▼ Sell | Tax Withholding | 2,920 | $29K | 1/30/2024 | View on chart |
| STTK | ▲ Buy | Grant | 46,475 | $0 | 1/10/2024 | View on chart |
| STTK | ▼ Sell | Tax Withholding | 2,987 | $30K | 1/10/2024 | View on chart |
| STTK | ▲ Buy | Grant | 37,875 | $0 | 1/25/2023 | View on chart |
| STTK | ▼ Sell | Tax Withholding | 2,987 | $9K | 1/10/2023 | View on chart |
| STTK | ▲ Buy | Grant | 34,738 | $0 | 1/10/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
UBS initiates coverage on Shattuck Labs with $17 price target
UBS has started covering Shattuck Labs, assigning a price target of $17. This new analyst view comes as the company prepares to present research at UEG Week 2026. The stock is currently trading near its 52-week low, making this fresh institutional attention a notable development for the company.
UBS initiates coverage on Shattuck Labs with $17 price target. UBS has started covering Shattuck Labs, assigning a price target of $17. This new analyst view comes as the company prepares to present research at UEG Week 2026. The stock is currently trading near its 52-week low, making this fresh institutional attention a notable development for the company.